Gossamer Bio

Big Pharma layoffs: BMS, Roche and Takeda axe hundreds of jobs
Big Pharma layoffs: BMS, Roche and Takeda axe hundreds of jobs
Medical Marketing and Media
layoffs
Bristol Myers Squibb
Roche
Takeda
Gossamer Bio
Novavax
Flag link:
Gossamer cuts loose 25% of its staff, ties future to phase 3 trial of tarnished Merck rival
Gossamer cuts loose 25% of its staff, ties future to phase 3 trial of tarnished Merck rival
Fierce Biotech
Gossamer Bio
layoffs
seralutinib
Merck
PAH
Flag link:
Gossamer Bio announces FDA has placed a partial clinical hold on all trials of GB5121 in response to serious adverse events
Gossamer Bio announces FDA has placed a partial clinical hold on all trials of GB5121 in response to serious adverse events
Investing.com
Gossamer Bio
GB5121
Flag link:
Gossamer pauses enrollment of lymphoma med, citing risk-benefit profile
Gossamer pauses enrollment of lymphoma med, citing risk-benefit profile
Fierce Biotech
Gossamer Bio
clinical trials
GB5121
lymphoma
Flag link:
Gossamer could put pressure on Merck
Gossamer could put pressure on Merck
EP Vantage
Merck
Gossamer Bio
PAH
sotatercept
United Therapeutics
ralinepag
Flag link:
Phase 2 deja vu for gossamer bio after ulcerative colitis med flops
Phase 2 deja vu for gossamer bio after ulcerative colitis med flops
Fierce Biotech
Gossamer Bio
ulcerative colitis
clinical trials
GB004
Flag link:
Gossamer Bio seeking out partners for failed DP2 antagonist, says it has 'viable path forward'
Gossamer Bio seeking out partners for failed DP2 antagonist, says it has 'viable path forward'
Fierce Biotech
Gossamer Bio
GB001
eosinophilic asthma
Flag link:
Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma
Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma
Xconomy
Gossamer Bio
clinical trials
asthma
eosinophilic asthma
GB001
Flag link:
Biotech companies raise cash as coronavirus updates lift stocks
Biotech companies raise cash as coronavirus updates lift stocks
BioPharma Dive
biotech
biotech stocks
COVID-19
Moderna Therapeutics
Bluebird Bio
Turning Point Therapeutics
Gossamer Bio
Krystal Biotech
Clovis Oncology
Gamida Cell
Bellerophon
Flag link:
A Look at 5 Big and Interesting Biotech IPOs for 2019
A Look at 5 Big and Interesting Biotech IPOs for 2019
BioSpace
IPOs
NASDAQ
Adaptive Biotechnologies
Genmab
Gossamer Bio
BridgeBio
Alector
Flag link:
Novartis' asthma drug fails in phase 3, raising doubts about Gossamer's prospects
Novartis' asthma drug fails in phase 3, raising doubts about Gossamer's prospects
Fierce Biotech
Novartis
clinical trials
fevipiprant
asthma
Gossamer Bio
Flag link:
BioSpace's List of February 2019 Life Science IPOs
BioSpace's List of February 2019 Life Science IPOs
BioSpace
IPOs
Shockwave Medical
Harpoon Therapeutics
Gossamer Bio
Alector
Hoth Therapeutics
Flag link:
Gossamer Bio Adds $276M in Second Biotech “Unicorn” IPO of 2019
Gossamer Bio Adds $276M in Second Biotech “Unicorn” IPO of 2019
Xconomy
Gossamer Bio
IPOs
Flag link:
With US government shutdown over, Gossamer reverts to traditional IPO plan
With US government shutdown over, Gossamer reverts to traditional IPO plan
Endpoints
Gossamer Bio
IPOs
government shutdown
Flag link:
Gosssamer Bio to Use 20 Day Rule for $230 Million IPO
Gossamer Bio
IPOs
Flag link:
Gossamer sets fixed share price for $230M IPO to sidestep shutdown
Gossamer sets fixed share price for $230M IPO to sidestep shutdown
BioCentury
Gossamer Bio
IPOs
government shutdown
Flag link:
Gossamer Bio Plans to Raise $264.5 Million with IPO
Gossamer Bio Plans to Raise $264.5 Million with IPO
BioSpace
Gossamer Bio
IPOs
Flag link:
Four Healthcare Startups Raised Over $130 Million Last Month
Four Healthcare Startups Raised Over $130 Million Last Month
Forbes
startups
23andMe
Gossamer Bio
Alector
Compass Therapeutics
Flag link: